---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Co-prescribed/Concomitant therapies. Topics: Medications excluded before randomization in the phase 3 trial, Required vaccination against encapsulated bacteria in the phase 3 trial, Medications excluded before randomization in the phase 2 trial, Required meningococcal vaccination in the phase 2 trial, and 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Medications excluded before randomization in the phase 3 trial

> “Concurrent or previous use of the following medication within the time periods specified below.”
> “Rituximab or other B-cell targeting therapies (ie, inebilizumab) within 6 months (180 days) prior to randomization (Day 1);”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)”
> “Previous treatment with claseprubart (DNTH103) or participation in a clinical trial with claseprubart.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.12-2"></a>

### Required vaccination against encapsulated bacteria in the phase 3 trial

> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.12-3"></a>

### Medications excluded before randomization in the phase 2 trial

> “Concurrent or previous use of the following medication within the time periods specified below.”
> “Rituximab within 6 months (180 days) prior to randomization (Day 1);”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1).”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.12-4"></a>

### Required meningococcal vaccination in the phase 2 trial

> “Vaccination against N. meningitidis with the quadrivalent meningococcal vaccine, and where available, meningococcal serotype B vaccine within 3 years prior to, or at the time of, initiating study drug.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.12-5"></a>

### Background immunosuppressive therapy at baseline in the phase 2 trial

| Characteristic | Placebo (N=22) | Claseprubart 300 mg every 2 weeks (N=21) | Claseprubart 600 mg every 2 weeks (N=22) |
| --- | --- | --- | --- |
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| Number of immunosuppressive therapies at baseline: 1, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| Number of immunosuppressive therapies at baseline: more than 1, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| Neonatal Fc receptor blocker use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement inhibitor use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |

Source: [Peric et al. (2026c)](https://investor.dianthustx.com/static-files/e11cda18-07b8-402e-b329-145717e8dc9b)

<a id="topic-2.1.2.12-6"></a>

### Rescue therapy and acetylcholinesterase inhibitor use in the phase 2 trial

> “During the RCT period two claseprubart patients received rescue treatment for the exacerbation and one patient had MG worsening attributed to missed pyridostigmine doses on the first day of claseprubart dosing (Day 1).”
> “During the OLE six patients received rescue therapy for the exacerbation.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
